{
    "clinical_study": {
        "@rank": "28366", 
        "arm_group": [
            {
                "arm_group_label": "Arm 1 (Normal renal function)", 
                "arm_group_type": "Experimental", 
                "description": "In the 15 day period that constitutes Part A of the trial, patients will receive a single oral dose of MLN9708 capsule on Day 1.\nPatients from Part A will then have the option of continuing the study by participating in Part B, starting immediately after Part A, where they will receive MLN9708 on Days 1, 8, and 15 of a 28-day cycle, in combination with dexamethasone orally on Days 1, 8, 15 and 22."
            }, 
            {
                "arm_group_label": "Arm 2 (Severe renal impairment)", 
                "arm_group_type": "Experimental", 
                "description": "In the 15 day period that constitutes Part A of the trial, patients will receive a single oral dose of MLN9708 capsule on Day 1 of a 15-day cycle.\nPatients from Part A will then have the option of continuing the study by participating in Part B, starting immediately after Part A, where they will receive MLN9708 on Days 1, 8, and 15 of a 28-day cycle, in combination with dexamethasone orally on Days 1, 8, 15 and 22."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a phase 1/1b, open-label, multicenter study of oral MLN9708 designed to assess the\n      pharmacokinetics (PK) of single dose MLN9708 in patients with normal renal function and in\n      patients with severe renal impairment (RI) (according to Cockcroft-Gault estimates).\n      Twenty-eight PK-evaluable patients will be enrolled in either 1 of the 2 arms of the study."
        }, 
        "brief_title": "Pharmacokinetics Study of Oral MLN9708 Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Multiple Myeloma", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female patients 18 years or older\n\n          -  Multiple myeloma (MM) diagnosed according to standard criteria\n\n          -  Patients with relapsed/refractory multiple myeloma after at least 1 prior therapy\n\n          -  A calculated creatinine clearance (CrCl) that meets entry criteria for enrollment\n             (ie, calculated CrCl either \u2265 90 or < 30 mL/min, including patients currently on\n             hemodialysis)\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2\n\n          -  Female patients who are post menopausal, surgically sterile, or agree to practice 2\n             effective methods of contraception through 90 days after the last dose of study drug\n             or agree to practice true abstinence\n\n          -  Male patients who agree to practice effective barrier contraception through 90 after\n             the last dose of study drug or agree to practice true abstinence\n\n          -  Voluntary written informed consent\n\n          -  Suitable venous access\n\n        Exclusion Criteria:\n\n          -  Female patients who are pregnant or breastfeeding\n\n          -  Failure to have recovered from clinically significant effects of prior chemotherapy\n             (defined as toxicity greater than Grade 1 with the exception of alopecia)\n\n          -  Major surgery or radiotherapy within 14 days before study drug administration\n\n          -  Dexamethasone (or equivalent systemic steroid) higher than the physiologic dosing\n             with 7 days before study drug administration\n\n          -  Central nervous system involvement\n\n          -  Infection requiring systemic antibiotic therapy or other serious infection within 14\n             days prior to first dose of study drug\n\n          -  Diagnosis of Waldenstrom's macroglobulinemia, POEMS (polyneuropathy, organomegaly,\n             endocrinopathy, monoclonal gammopathy, and skin changes) syndrome, plasma cell\n             leukemia, myeloproliferative syndrome, or primary amyloidosis (with the exception of\n             patients in whom amyloidosis has been documented as a complication of MM, who will be\n             evaluated on a case-by-case basis for trial participation)\n\n          -  Systemic treatment with strong and moderate inhibitors of CYP1A2, strong and moderate\n             inhibitors of CYP3A, or clinically significant CYP3A inducers or use of Ginkgo biloba\n             or St. John's wort within 14 days before the first dose of study drug\n\n          -  Evidence of uncontrolled cardiovascular conditions\n\n          -  Ongoing or active systemic infection, active hepatitis B or C virus infection, or\n             known human immunodeficiency virus (HIV) positive\n\n          -  Comorbid systemic illness or psychiatric illness that could interfere with study\n             completion\n\n          -  Known allergy to study medications\n\n          -  Inability to swallow oral medication or condition that could interfere with oral\n             absorption or tolerance of treatment\n\n          -  Diagnosis or treated for another invasive malignancy within 2 years before\n             enrollment, OR previously diagnosed with another malignancy with current evidence of\n             residual disease.  Patients with nonmelanoma skin cancer or carcinoma in situ of any\n             type are not excluded if they have undergone complete resection"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "28", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01830816", 
            "org_study_id": "C16015", 
            "secondary_id": "2012-004516-64"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Arm 1 (Normal renal function)", 
                    "Arm 2 (Severe renal impairment)"
                ], 
                "intervention_name": "MLN9708", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Arm 1 (Normal renal function)", 
                    "Arm 2 (Severe renal impairment)"
                ], 
                "intervention_name": "dexamethasone", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Dexamethasone acetate", 
                "Dexamethasone", 
                "Dexamethasone 21-phosphate", 
                "BB 1101"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Relapsed", 
            "Refractory", 
            "Multiple Myeloma"
        ], 
        "lastchanged_date": "February 19, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia"
                    }, 
                    "name": "Winship Cancer Institute at Emory University"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fairway", 
                        "country": "United States", 
                        "state": "Kansas"
                    }, 
                    "name": "University of Kansas Cancer Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York"
                    }, 
                    "name": "Mount Sinai Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }, 
                    "name": "Sarah Cannon Research Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Laredo", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78041"
                    }, 
                    "name": "Institute of Oncology Hematology Biomedical Research LLC"
                }, 
                "status": "Withdrawn"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase 1/1b Pharmacokinetics Study of Oral MLN9708 Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients With Normal Renal Function or Severe Renal Impairment", 
        "overall_contact": {
            "email": "medical@mlnm.com", 
            "last_name": "For an updated listing of recruitment sites contact: Millennium  Medical and Drug Information Center", 
            "phone": "1-877-674-3784"
        }, 
        "overall_official": {
            "affiliation": "Millennium Pharmaceuticals, Inc.", 
            "last_name": "Medical Monitor", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Plasma PK parameter", 
                "measure": "Mean single-dose maximum (peak) concentration (Cmax) of MLN9708", 
                "safety_issue": "No", 
                "time_frame": "Assessed on Days 1-15 of Part A"
            }, 
            {
                "description": "Plasma PK parameter", 
                "measure": "Area under the plasma concentration versus time curve from time zero to the time of last quantifiable concentration (AUC0-last) of MLN9708", 
                "safety_issue": "No", 
                "time_frame": "Assessed on Days 1-15 of Part A"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01830816"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Safety and tolerability of MLN9708 plus dexamethasone", 
                "measure": "Number of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "From administration of the first dose of study drug and through 30 days after the last dose of study drug, approximately 13 months"
            }, 
            {
                "description": "Proportion of patients who achieved partial response (PR) or better", 
                "measure": "Number of patients with overall response (OR)", 
                "safety_issue": "No", 
                "time_frame": "Assessed every 8 weeks (length of the endpoint assessment period is projected to be approximately 13 months)"
            }, 
            {
                "description": "The time from the date of first documentation of a PR or better to the date of first documentation of progressive disease (PD) for responders", 
                "measure": "Duration of response", 
                "safety_issue": "No", 
                "time_frame": "Assessed every 8 weeks until disease progression, approximately 13 months"
            }, 
            {
                "description": "The time from the date of first dose of study drug to the date of first documentation of PD.", 
                "measure": "Time to progression", 
                "safety_issue": "No", 
                "time_frame": "Assessed every 8 weeks until disease progression, approximately 13 months"
            }, 
            {
                "description": "The time from the date of first dose of study drug to the date of first documentation of PD or death due to any cause, whichever occurs first.", 
                "measure": "Progression free survival rate", 
                "safety_issue": "No", 
                "time_frame": "Assessed every 8 weeks until disease progression or death, approximately 13 months"
            }, 
            {
                "description": "The time from the date of initiation of treatment until the date when criteria for renal response are first met for patients in Arm 2.", 
                "measure": "Time to renal response (Arm 2)", 
                "safety_issue": "No", 
                "time_frame": "Assessed every 4 weeks until renal response, approximately 13 months"
            }, 
            {
                "description": "The time from the date of first documentation of a renal minor response or better to the date of first documentation of progression of renal disease (renal PD) for renal responders in Arm 2.", 
                "measure": "Duration of renal response (Arm 2)", 
                "safety_issue": "No", 
                "time_frame": "Assessed every 4 weeks until renal disease progression, approximately 13 months"
            }, 
            {
                "description": "The proportion of patients who achieved a renal minor response or better in Arm 2.", 
                "measure": "Renal response rate (Arm 2)", 
                "safety_issue": "No", 
                "time_frame": "Assessed every 4 weeks until renal response, approximately 13 months"
            }
        ], 
        "source": "Millennium Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Millennium Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}